DMD Simcyp

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Meloche, C. A.
Right arrow Articles by Falany, C. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Meloche, C. A.
Right arrow Articles by Falany, C. N.

Vol. 30, Issue 5, 582-585, May 2002

Sulfation of Budesonide by Human Cytosolic Sulfotransferase, Dehydroepiandrosterone-Sulfotransferase (DHEA-ST)

Connie A. Meloche, Vyas Sharma, Stellan Swedmark, Paul Andersson, and Charles N. Falany

Department of Pharmacology and Toxicology, University of Alabama at Birmingham, Birmingham, Alabama (C.A.M., C.N.F.); College of Pharmacy, University of Iowa, Iowa City, Iowa (V.S.); AstraZeneca, Södertälje, Sweden (S.S.); and AstraZeneca, Lund, Sweden (P.A.)

Budesonide, a synthetic glucocorticosteroid, is used in the treatment of asthma and allergic reactions, rhinitis, and inflammatory bowel disease. It is distributed as a mixture of two epimers, 22R and 22S, and has a high ratio of topical to systemic activity due to extensive first-pass metabolism to metabolites with minimal activity. Previous studies have shown that the epimers are metabolized by the cytochrome P450 monooxygenase system. Metabolism and inactivation of the epimers by the phase II enzymes has not been well characterized. This study describes the conjugation of budesonide by human cytosolic sulfotransferases (SULTs). Seven human SULTs were analyzed to determine which were capable of catalyzing the sulfation of the epimers of budesonide. Only dehydroepiandrosterone-sulfotransferase (DHEA-ST, SULT2A1) was capable of forming a sulfated budesonide product. The epimeric forms of budesonide display different kinetic activities with the 22R epimer having a 3.5-fold greater rate of sulfation activity than the 22S epimer. The structure of budesonide shows two hydroxyl sites that are potential sites for sulfate conjugation, but analysis by mass spectrometry indicates the formation of only a monosulfated budesonide product. A modeling approach was used to define the site of sulfation as that of the 21-hydroxyl group. Although sulfation of budesonide by DHEA-ST may not be an important factor in its use as an antiasthmatic, intestinal and hepatic sulfation will be important for its proposed systemic use as an anti-inflammatory agent.

Copyright © 2002 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 Drug Metab. Dispos.Home page
L. Senggunprai, K. Yoshinari, and Y. Yamazoe
Selective Role of Sulfotransferase 2A1 (SULT2A1) in the N-Sulfoconjugation of Quinolone Drugs in Humans
Drug Metab. Dispos., August 1, 2009; 37(8): 1711 - 1717.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
L. Wang, N. Raghavan, K. He, J. M. Luettgen, W. G. Humphreys, R. M. Knabb, D. J. Pinto, and D. Zhang
Sulfation of O-Demethyl Apixaban: Enzyme Identification and Species Comparison
Drug Metab. Dispos., April 1, 2009; 37(4): 802 - 808.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol SciHome page
Y. Alnouti
Bile Acid Sulfation: A Pathway of Bile Acid Elimination and Detoxification
Toxicol. Sci., April 1, 2009; 108(2): 225 - 246.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
J. Hoon Lee, H. Gong, S. Khadem, Y. Lu, X. Gao, S. Li, J. Zhang, and W. Xie
Androgen Deprivation by Activating the Liver X Receptor
Endocrinology, August 1, 2008; 149(8): 3778 - 3788.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
I. Echchgadda, C. S. Song, T. Oh, M. Ahmed, I. J. De La Cruz, and B. Chatterjee
The Xenobiotic-Sensing Nuclear Receptors Pregnane X Receptor, Constitutive Androstane Receptor, and Orphan Nuclear Receptor Hepatocyte Nuclear Factor 4{alpha} in the Regulation of Human Steroid-/Bile Acid-Sulfotransferase
Mol. Endocrinol., September 1, 2007; 21(9): 2099 - 2111.
[Abstract] [Full Text] [PDF]

Home page
 PsychosomaticsHome page
G. H. Wynn, N. B. Sandson, and K. L. Cozza
Gastrointestinal Medications
Psychosomatics, February 1, 2007; 48(1): 79 - 85.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
C. S. Song, I. Echchgadda, Y.-K. Seo, T. Oh, S. Kim, S.-A Kim, S. Cho, L. Shi, and B. Chatterjee
An Essential Role of the CAAT/Enhancer Binding Protein-{alpha} in the Vitamin D-Induced Expression of the Human Steroid/Bile Acid-Sulfotransferase (SULT2A1)
Mol. Endocrinol., April 1, 2006; 20(4): 795 - 808.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
J. L. Falany, D. E. Pilloff, T. S. Leyh, and C. N. Falany
SULFATION OF RALOXIFENE AND 4-HYDROXYTAMOXIFEN BY HUMAN CYTOSOLIC SULFOTRANSFERASES
Drug Metab. Dispos., March 1, 2006; 34(3): 361 - 368.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
I. Echchgadda, C. S. Song, A. K. Roy, and B. Chatterjee
Dehydroepiandrosterone Sulfotransferase Is a Target for Transcriptional Induction by the Vitamin D Receptor
Mol. Pharmacol., March 1, 2004; 65(3): 720 - 729.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
B. Ma, M. Shou, and M. L. Schrag
SOLVENT EFFECT ON cDNA-EXPRESSED HUMAN SULFOTRANSFERASE (SULT) ACTIVITIES IN VITRO
Drug Metab. Dispos., November 1, 2003; 31(11): 1300 - 1305.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2002 by the American Society for Pharmacology and Experimental Therapeutics.